Diabetic Neuropathy

  • Russell Chin
  • Michael Rubin


Diabetes mellitus (DM) is the most common cause of peripheral neuropathy in the United States. Approximately 16 million Americans suffer from diabetes and as many as 100% may have neuropathy. Evidence suggests that the incidence of neuropathy increases with the duration and severity of disease, and that strict glycemic control delays its development and progression. 1,2


Carpal Tunnel Syndrome Diabetic Neuropathy Aldose Reductase Autonomic Neuropathy Nerve Conduction Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986, 1993.Google Scholar
  2. 2.
    Melton LJ III, Dyck PJ. Epidemiology, 239–252. in Dyck PJ, Thomas PK, et al (eds): Diabetic Neuropathy. WB Saunders, Philadelphia, 1999.Google Scholar
  3. 3.
    Thomas PK, Tomlinson DR: Diabetic and hypoglycemic neuropathy. p. 1219–1250. in Dyck PJ, Thomas PK, et al (eds). Peripheral Neuropathy. W.B. Saunders, Philadelphia, 1993.Google Scholar
  4. 4.
    Dyck PJ, Karnes JL, O’Brien PC, et al. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 42: 1164–70, 1992.PubMedCrossRefGoogle Scholar
  5. 5.
    Pirart J. Diabetes Mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1: 168–188, 1978.Google Scholar
  6. 6.
    Boulton Andrew JM, Malik RA. Diabetic Neuropathy. Medical Clinics of North America 82: 909–929, 1998.PubMedCrossRefGoogle Scholar
  7. 7.
    Vinik AL, Park TS, et al. Diabetic neuropathies. Diabetologia 43: 957–973, 2000.PubMedCrossRefGoogle Scholar
  8. 8.
    Halar EM, Graf RJ, Halter JB, Brozovich FV, Soine TL. Diabetic neuropathy: a clinical, laboratory, and electrodiagnostic study. Arch Phys Med Rehabil 63: 298–303, 1982.PubMedGoogle Scholar
  9. 9.
    Niakan E, Harati Y. Sympathetic skin response in diabetic peripheral neuropathy. Muscle Nerve 11: 261–264, 1988.PubMedCrossRefGoogle Scholar
  10. 10.
    Blau, RH. Diabetic Neuropathic Cachexia: Report of a Woman with this syndrome and review of the literature. Arch Intern Med 143: 2011–2012, 1983.PubMedCrossRefGoogle Scholar
  11. 11.
    Archer AG, Watkins PJ, Thomas PK, et al. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry 46: 491, 1983.PubMedCrossRefGoogle Scholar
  12. 12.
    Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med 49: 95–108, 1980.PubMedGoogle Scholar
  13. 13.
    Aronson D. Pharmacologic modulation of autonomic tone: implications for the diabetic patient. Diabetologia 40: 476–481, 1997.PubMedCrossRefGoogle Scholar
  14. 14.
    Schnell O, Schwarz A, Becker DM, Standl E. Autoantibodies against autonomic nervous tissues in type 2 diabetes. Exp Clin Endocrinol Diabetes (Germany) 108: 181–6, 2000.CrossRefGoogle Scholar
  15. 15.
    Wein TH, Albers JW. Diabetic neuropathies. Phys Med and Rehab Clinics of North America 12 (2): 307–320, 2001.Google Scholar
  16. 16.
    Barohn RJ, Sahenk Z, Warmolts JR, Mendell JR. The Bruns-Garland Syndrome (Diabetic Amyotrophy): Revisited 100 Years Later. Arch Neurol 48: 1130–1135, 1991.PubMedCrossRefGoogle Scholar
  17. 17.
    Pascoe MK, Low PA, Windebank AJ, Litchy WJ. Subacute diabetic proximal neuropathy. Mayo Clin Proc 72: 1123–1132, 1997.PubMedCrossRefGoogle Scholar
  18. 18.
    Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 35: 559–569, 1994.PubMedCrossRefGoogle Scholar
  19. 19.
    Stewart JD. Diabetic truncal neuropathy: Topography of the sensory deficit. Ann Neurol 25: 233–238, 1989.PubMedCrossRefGoogle Scholar
  20. 20.
    Sun SF, Streib EW. Diabetic thoracoabdominal neuropathy: Clinical and electrodiagnostic features. Ann Neurol 9: 75–79, 1981.PubMedCrossRefGoogle Scholar
  21. 21.
    Goldstein JE, Cogan DG. Diabetic ophthalmoplegia with special reference to the pupil. Arch Ophthalmol 64: 592, 1960.PubMedCrossRefGoogle Scholar
  22. 22.
    Jacobson DM. Pupil involvement in patients with diabetes-associated oculomotor nerve palsy. Arch Ophthalmol 116: 723–727, 1998.PubMedCrossRefGoogle Scholar
  23. 23.
    Richards BW, Jones FR, Younge BR. Causes and prognosis in 4,278 cases of paralysis of the oculomotor, trochlear, and abducens cranial nerves. Am J Ophthalmol 113: 489–496, 1992.PubMedGoogle Scholar
  24. 24.
    Dahlin LB, Meiri KF, McLean WG, et al. Effects of nerve compression on fast axonal transport in streptozotocin-induced diabetes mellitus. Diabetologica 29: 181–185, 1986.CrossRefGoogle Scholar
  25. 25.
    Shahani B, Spalding JMK. Diabetes mellitus presenting with bilateral foot-drop. Lancet 2: 930–931, 1969.PubMedCrossRefGoogle Scholar
  26. 26.
    Dyck PJ, Sherman WR, Hallcher LM et al. Human diabetic endoneurial sorbitol, fructose, and myoinositol related to sural nerve morphometry. Ann Neurol. 8: 590–6, 1980.PubMedCrossRefGoogle Scholar
  27. 27.
    Airey M, Bennet C, Nicolucci A, Williams R. Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev 285 (2):CD002182, 2000.Google Scholar
  28. 28.
    Newrick PG, Wilson AJ, Jakubowski J, et al. Sural nerve oxygen tension in diabetes. Brit Med J 293: 1053–1054, 1986.CrossRefGoogle Scholar
  29. 29.
    Tuck RR, Schmelzer JD, Low PA. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 107: 935–950, 1984.PubMedCrossRefGoogle Scholar
  30. 30.
    Low PA, Tuck RR, Dyck PJ, et al. Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. Proc Natl Acad Sci USA 81: 6894–6898, 1984.PubMedCrossRefGoogle Scholar
  31. 31.
    Low PA, Schmelzer JD, Ward KK, et al. Effect of hyperbaric oxygenation on normal and chronic streptozotocin diabetic peripheral nerves. Exp Neurol 99: 201–212, 1988.PubMedCrossRefGoogle Scholar
  32. 32.
    Watkins PJ, Gayle C, Alsanjari N, et al. Severe sensory autonomic neuropathy and endocrinopathy in insulin dependent diabetes. Q J Med 88: 795–804, 1999.Google Scholar
  33. 33.
    Kelkar P, Masood M, Parry GJ. Distinctive pathologic findings in proximal diabetic neuropathy (diabetic amyotrophy). Neurology 55: 83–88, 2000.PubMedCrossRefGoogle Scholar
  34. 34.
    Kimura J. Electrodiagnosis in diseases of nerve and muscle: principles and practice, 3rd Ed. Oxford University Press, New York. 2001.Google Scholar
  35. 35.
    Low PA, Dotson RM. Symptomatic Treatment of Painful Neuropathy. JAMA 280: 1863–1864, 1998.PubMedCrossRefGoogle Scholar
  36. 36.
    Max MB, Lynch SA, Muir J et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326 (19): 1250–1256, 1992.PubMedCrossRefGoogle Scholar
  37. 37.
    Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 55: 915–920, 2000.PubMedCrossRefGoogle Scholar
  38. 38.
    Bennet GJ, Dworkin RH, Nicholson B. Anticonvulsant Therapy in the Treatment of Neuropathic Pain. Neurology Treatment Updates. Medscape. Accessed May 9, 2001Google Scholar
  39. 39.
    Tremont-Lukats IW, Megeff C, Backonja M-M. Anticonvulsants for Neuropathic Pain Syndromes: Mechanisms of action and place in therapy. Drugs 60 (5): 1029–1052, 2000.PubMedCrossRefGoogle Scholar
  40. 40.
    Gorson KC, Schott C, Herman R, et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 66: 251–252, 1999.PubMedCrossRefGoogle Scholar
  41. 41.
    McCleane G. Two hundred mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomized, double-blind, placebo controlled trial. Pain 83: 105–107, 1999.PubMedCrossRefGoogle Scholar
  42. 42.
    Jarvis B, Coukell AJ. Mexiletine: a review of its therapeutic use in painful diabetic neuropathy. Drugs 56 (4): 691–707, 1998.PubMedCrossRefGoogle Scholar
  43. 43.
    Rains C, Bryson HM. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging 7 (4): 317–328, 1995.PubMedCrossRefGoogle Scholar
  44. 44.
    Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 50 (6): 1842–1846, 1998.PubMedCrossRefGoogle Scholar
  45. 45.
    Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes treatment on nerve conduction in the diabetes control and complications trial. Ann Neurol 38: 869–880, 1995.Google Scholar
  46. 46.
    Feldman EL, Stevens MJ, Greene DA. Clinical management of diabetic neuropathy: an overview. In Veves A (ed): Clinical Management of Diabetic Neuropathy. Humana Press, Totowa, NJ, 1998.Google Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Russell Chin
  • Michael Rubin

There are no affiliations available

Personalised recommendations